Regulatory Expertise Privately-held boutique regulatory consulting firm with a leadership team led by an experienced senior regulatory affairs professional and a track record of IND filings, suggesting strong opportunities for CRO-style partnerships and regulatory strategy engagements with biopharma clients in early to late development.

Recent IND Activity Recent experience includes two biologics INDs in cardiovascular disease indications, plus proven ability to plan, write, and file INDs with no clinical holds, signaling potential to win new IND/CMC projects and accelerate development timelines for biotech sponsors.

FDA Collaboration Deep and current engagement with FDA on CMC issues for lyophilized biologics, mid-development formulation changes, potency method development, and negotiating safety/toxicity requirements, indicating strong appeal for sponsors seeking regulatory risk mitigation and FDA-aligned pathways.

Service Footprint Comprehensive regulatory services across global management, quality assurance, CMC for biologics and small molecules, PK/PD/toxicology planning, clinical operations, and biosimilar/combination product strategies, enabling cross-sell opportunities within small to mid-sized biopharma portfolios.

Growth Indicators Revenue range ($1M-$10M) paired with a lean team (2-10 employees) suggests agile, high-value engagements and potential for scalable partnerships, as well as expansion opportunities with larger sponsors seeking boutique regulatory support.